• 1.

    Huang ES, Basu A, O'Grady M, et al: Projecting the future diabetes population size and related costs for the US. Diabetes Care 32: 2225, 2009.

    • Crossref
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 2.

    Snyder RJ, Kirsner RS, Warriner RA, et al: Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Management 56(suppl 4): S1, 2010.

    • Search Google Scholar
    • Export Citation
  • 3.

    Boulton AJ, Kirsner RS, Vileikyte L: Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 351: 48, 2004.

  • 4.

    Margolis D, Kantor J, Berlin J: Healing of neuropathic ulcers receiving standard treatment: a meta-analysis. Diabetes Care 22: 692, 1999.

  • 5.

    Shores JT, Gabriel A, Gupta S: Skin substitutes and alternatives: a review. Adv Skin Wound Care 20: 493, 2007.

  • 6.

    Niknejad H, Peirovi H, Jorjani M, et al: Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 15: 88, 2008.

  • 7.

    Bennett JP, Matthews R, Faulk WP: Treatment of chronic ulceration of the legs with human amnion. Lancet 1: 1153, 1980.

  • 8.

    Baradaran-Rafii A, Aghayan H, Arjmand B, et al: Amniotic membrane transplantation. Iran J Ophthalmic Res 2: 58, 2007.

  • 9.

    Adly OA, Moghazy AM, Abbas AH, et al: Assessment of amniotic and polyurethane membrane dressings in the treatment of burns. Burns 36: 703, 2010.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 10.

    Tao H, Fan H: Implantation of amniotic membrane to reduce postlaminectomy epidural adhesions. Eur Spine J 18: 1202, 2009.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 11.

    John T: Human amniotic membrane transplantation: past, present, and future. Ophthalmol Clin North Am 16: 43, 2003.

  • 12.

    Akle C, Adinolfi M, Welsh K, et al: Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet 2: 1003, 1981.

  • 13.

    Hao Y, Ma DH, Hwang DG, et al: Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea 19: 348, 2000.

  • 14.

    King AE, Paltoo A, Kelly RW, et al: Expression of natural antimicrobials by human placenta and fetal membranes. Placenta 28: 161, 2007.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 15.

    Gruss JS, Jirsch DW: Human amniotic membrane: a versatile wound dressing. Can Med Assoc J 118: 1237, 1978.

Using Amniotic Membrane Allografts in the Treatment of Neuropathic Foot Ulcers

Alap P. Shah Foot and Ankle of West Georgia, Columbus, GA.

Search for other papers by Alap P. Shah in
Current site
Google Scholar
PubMed
Close
 DPM, CWS
Restricted access

Neuropathic foot ulcers are a common complication in patients with diabetes. These ulcers are often slow to heal and can lead to infection, further tissue destruction, osteomyelitis, and amputation. These patients pose a challenge to clinicians who must determine the best treatment options while balancing the risks, benefits, and costs. Conservative therapies often present disappointing results, and a number of newer “biologic bandages” have been developed to better assist the healing process. We describe results from diabetic patients with neuropathic foot ulcers treated with a new amniotic membrane–based allograft.

Corresponding author: Alap P. Shah, DPM, CWS, Foot and Ankle of West Georgia, 2751-A Warm Springs Road, Columbus, GA 31904. (E-mail: alapshahdpm@gmail.com)